Resource Room
Press releases
06.03.2019
04.01.2019
12.10.2018
10.19.2018
08.15.2018
QED Tx – A New Company Working on a Treatment for Achondroplasia
01.30.2018
Links to infigratinib clinical trials
Phase 3 study of BJG398 (oral infigratinib) in first line cholangiocarcinoma with FGFR2 gene fusions/translocations
National Institutes of Health website.
A phase II, single arm study of BGJ398 in patients with advanced cholangiocarcinoma
National Institutes of Health website.
BGJ398 in non-muscle-invasive urothelial carcinoma of the bladder
National Institutes of Health website.
BGJ398 in treating patients with FGFR positive recurrent head and neck cancer
National Institutes of Health website.
Infigratinib scientific resources
06.03.2019
Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Javle M et al. Presented at the American Society of Clinical Oncology 2019 Annual Meeting; May 31-June 4, 2019; Chicago, IL.
06.03.2019
Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results
Dizman N et al. Presented at the American Society of Clinical Oncology 2019 Annual Meeting; May 31-June 4, 2019; Chicago, IL.
10.19.2018
A phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor (TKI), in patients with previously-treated advanced cholangiocarcinoma containing FGFR2 fusions
Javle M et al. Presented at the European Society for Medical Oncology 2018 Congress; October 19-23, 2018; Munich, Germany.
05.30.2018
Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations
Pal SK et al. Published in Cancer Discovery.
04.11.2016
Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model
Komla-Ebri D et al. Published in The Journal of Clinical Investigation.
More about FGFR and FGFR-driven diseases
02.13.2019
About biliary cancer
Dana-Farber Cancer Institute website.
01.17.2018
Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype
Jain A et al. Published in JCO Precision Oncology.
06.07.2017
Comprehensive genomic characterization of upper tract urothelial carcinoma
Moss TJ et al. Published in European Urology.
01.22.2015
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Sia D et al. Published in Nature Communications.
12.23.2014
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles MA, Hurst CD. Published in Nature Reviews Cancer.
04.25.2014
Second-line chemotherapy in advanced biliary cancer: a systematic review
Lamarca A et al. Published in Annals of Oncology.
Contact Us
75 Federal Street
San Francisco, CA 94107
650-231-4088